2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis

By sjmartinez • October 30, 2024

Bhimraj A, Falck-Ytter Y, Kim AY, Li JZ, Baden LR, Johnson S, Shafer RW, Shoham S, Tebas P, Bedimo R, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Martin GS, MacBrayne C, Nadig N, Nakamura MM, Shumaker AH, Tien P, Loveless J, Morgan RL, Gandhi RT. 2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis. Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093/cid/ciae435. Epub ahead of print. PMID: 39471458.

Tags: covid-19, guideline, Infectious Diseases, pemivibart, Pre-exposure prophylaxis, Publications, SARS-CoV-2

Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide

Olson TE, Lloyd TS, Hamad CD, Chun RF, Wiener J, Golzar A, Mehany J, Shahamatdar S, Kittredge A, Pearce L, Francis KP, Obeidin F, Holly[...]

HIV and Syphilis Testing Among Patients Tested for Gonorrhea and Chlamydia in Emergency Departments

Sherwood K, Zhang N, David H, Dekker A, Garner O, Samuels E, Adamson P. HIV and Syphilis Testing Among Patients Tested for Gonorrhea and Chlamydia[...]

Implementation of a One Health Surveillance System in the Democratic Republic of the Congo

Kinzie PR, Lombe B, Merritt S, Halbrook M, Vakaniaki EH, Mukadi P, L'k'ye AM, Mona J, Kanonge D, Mfwangkang M, Witte D, Melofchik C, Muyembe-Tamfum[...]